Bicycle Therapeutics Raises £3.75M in Funding
Bicycle Therapeutics, a Cambridge, U.K.-based biotechnology company, has raised £3.75m (approximately $6m) in new funding.
Backers include existing investors Atlas Venture, Novartis Venture Fund, SR One and SV Life Sciences and new investor Astellas Venture Management, the venture capital arm of Astellas Pharma.
The company intends to use the capital for drug discovery.
Co-founded by Sir Gregory Winter and Professor Christian Heinis and led by Rolf Günther, CEO, and Dr. John Tite, CSO, Bicycle Therapeutics has developed a proprietary bicyclic peptide technology that enables the discovery of a new class of drug candidates for oncology, metabolic and inflammatory diseases.